Breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors MINNEAPOLIS, June 8, 2020 /PRNewswire/ — HistoSonics, developer of a non-invasive robotic platform and sonic beam therapy, announced today that it has closed $40 million in an …
Latest News From Lumira Ventures
UCB Acquires Engage Therapeutics: Staccato® Alprazolam – A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
– Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients – Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145 million, total potential consideration of up to US$ 270 …
Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020
Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis. AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or adverse events greater than Grade 2 were observed. The MTD was not reached. AVID200 …
IMV Announces Proposed $22.3 Million Private Placement
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the “Private Placement”) of 7,797,203 units of the Company (each, a “Unit”) at the market price of …
Edesa Biotech and Light chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development company, for an exclusive worldwide …
Aurinia Initiates rolling Submission of NDA to U.S. FDA
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced today that the Company has initiated a Rolling Submission of its New Drug Application …
G1 Therapeutics Strengthens Executive Team & Board of Directors
RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer (CCO). Related Article: G1 …
Edesa Biotech to Develop Novel Treatment for Vitiligo
TORONTO, ON / ACCESSWIRE / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo as well as other indications. Related Article: …
Aurinia Partners with National Kidney Foundation on Awareness Initiative
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced new initiatives to support the lupus nephritis (LN) community …
Engage Therapeutics’ Phase 2b StATES Study Meets Primary Endpoint
SUMMIT, N.J. (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATES study of Staccato® alprazolam met its primary …
Satsuma Reports Q4 2019 & FY2019 Financial Results
SOUTH SAN FRANCISCO, Calif. (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported financial results for the quarter and full-year ended December 31, 2019 and summarized recent business results. Related Article: Satsuma Pharmaceuticals Appoints Rob …
Cardiac Dimensions Hires Gretchen Gary as VP of Global Therapy Development
KIRKLAND, Wash. /PRNewswire/ — Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the hiring of Gretchen Gary as Vice President of Global Therapy Development. …
Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer
South San Francisco, CA – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob Janosky to the newly created position of Chief Commercial Officer. As Satsuma’s Chief Commercial Officer, Mr. Janosky will be responsible …
Aurinia Reports Q4 2019 & Fiscal Year 2019 Results
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless specified otherwise, are expressed in U.S. dollars “2019 …
Medexus Expands US Product Portfolio with IXINITY® Acquisition
TORONTO and CHICAGO and MONTREAL (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the Company, through its US-based subsidiary, acquired Aptevo BioTherapeutics LLC, a Delaware limited liability company owning the worldwide …